SomnoMed Limited (ASX:SOM)

Market Cap	137.23M
Revenue (ttm)	100.25M
Net Income (ttm)	-6.00M
Shares Out	216.11M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	219.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,329
Average Volume	46,661
Open	0.6050
Previous Close	0.6350
Day's Range	0.5800 - 0.6350
52-Week Range	0.2400 - 0.6950
Beta	1.03
RSI	57.92
Earnings Date	May 29, 2025

About SomnoMed

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper te...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1987
• Employees: 300
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SOM

Financial Performance

In 2024, SomnoMed's revenue was 91.65 million, an increase of 9.61% compared to the previous year's 83.62 million. Losses were -12.24 million, 53.0% more than in 2023.